CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical stakeholders.
Elina Koustoumpardi is a panelist during the session titled “New Developments in Merger Control” discussing:
- Update on new merger guidelines, national approaches and calls for new call-in powers
- Current approaches to killer acquisitions
- Key learning from Novo Holdings acquisition of Catalent: the importance of scale, role of efficiencies and innovation and the implications for merger guidelines
- Navigating the uncertainty around commercial transactions: are there risks posed by even minor interests in acquisitions?
For more information on this event, click here.
